Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison

We conducted unanchored matching-adjusted indirect comparisons (MAICs) of the BCMA × CD3 bispecific antibodies, linvoseltamab and elranatamab, in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). Patient-level data from BCMA-targeted therapy-naïve patients in LINKER-MM1 (linvoseltamab; NCT03761108; n = 107; data cutoff (DCO): 07/2024; median follow-up: 21.3 months) were matched to MagnetisMM-3 Cohort A (elranatamab; NCT04649359; N = 123; DCO: 09/2024; median follow-up: 33.9 months). Linvoseltamab demonstrated significantly (p < 0.05) higher overall response (71.5% vs. 61.0%) and complete response or better rates (50.5% vs. 37.4%), and numerically higher very good partial response or better rate (65.0% vs. 56.1%; p = 0.09) versus elranatamab. Duration of response (hazard ratio [HR] = 0.82; p = 0.54), progression-free survival (HR = 0.86; p = 0.50), and overall survival (OS) (HR = 0.67; p = 0.08) were numerically but not statistically significantly favorable for linvoseltamab. When measured using restricted mean survival time, OS significantly favored linvoseltamab (difference: 3.47 months; p = 0.04). This MAIC of linvoseltamab versus elranatamab suggests linvoseltamab offers favorable efficacy in TCE RRMM.